Latest updates for Mavenclad

Fresh curated links around Mavenclad are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Recent items include:

  • Mavenclad may pull double duty for MS and other autoimmune conditions
  • Cladribine
  • Treatments (Part 5).Who is using alemtuzumab?

Post angles to try

Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

multiplesclerosisnewstoday.com /1 week ago

Mavenclad may pull double duty for MS and other autoimmune conditions

In addition to controlling multiple sclerosis (MS), the approved therapy Mavenclad (cladribine) may also help manage certain coexisting autoimmune diseases, potentially allowing so...

Read source
multiple-sclerosis-research.org /1 month ago

Cladribine

We talked about effects of CD20 on CNS cells. The paper today helps support the view of the event in the brain as it relates to cladribine. It shows that cladribine is getting MS u...

Read source
multiple-sclerosis-research.org /1 week ago

Treatments (Part 5).Who is using alemtuzumab?

So we will do the drug use of alemtuzumab today for year 2025-2026 so down load the 12 CSV files for April-2025-March 2026. I have selected alemtuzmab as this will be the quickest...

Read source
multiplesclerosisnewstoday.com /1 month ago

CMSC 2026: Kesimpta outperforms Aubagio in highly active relapsing MS

Kesimpta (ofatumumab) was more effective than Aubagio (teriflunomide) at suppressing disease activity in people with highly active, relapsing forms of multiple sclerosis (MS), acco...

Read source
multiple-sclerosis-research.org /1 month ago

Drilling Down on Cladribine biology

This study uses high end technology to delve into the “unclear” and the conclusion is that cladribine gives long-term depletion of memory B cells and then we can say “Should have g...

Read source
multiplesclerosisnewstoday.com /1 month ago

CMSC 2026: Trial data show frexalimab benefits lasting 3 years

Three years of treatment with Sanofi’s investigational antibody therapy frexalimab was associated with persistently low disease activity and no new safety concerns in people with r...

Read source
multiple-sclerosis-research.org /1 month ago

Switching made easier

Schoof LG, Hogenboom L, van Kempen ZL, Killestein J, van Oosten BW, Strijbis EM. Reinitiating ocrelizumab with a full 600 mg dose after extended treatment interruption: No increa...

Read source
drugs.com /1 month ago

Drug Effective In Slowing Progressive MS, Trial Shows

FRIDAY, May 29, 2026 — An already-approved MS drug can significantly slow progression in people with primary progressive multiple sclerosis (PPMS), according to a new study.Patien...

Read source
drugs.com /1 month ago

Ocrelizumab Effective In Slowing Progressive MS, Trial Shows

FRIDAY, May 29, 2026 — An already-approved MS drug can significantly slow progression in people with primary progressive multiple sclerosis (PPMS), according to a new study. Patien...

Read source
multiplesclerosisnewstoday.com /3 weeks ago

Real-world study finds fewer MS relapses with Vumerity vs. Tecfidera

Despite being converted into the same active ingredient, the newer multiple sclerosis (MS) drug Vumerity (diroximel fumarate) is associated with significantly lower relapse rates t...

Read source
multiplesclerosisnewstoday.com /1 month ago

Briumvi outperforms Aubagio when given as first MS therapy, per trial data

First-line treatment with TG Therapeutics’ Briumvi (ublituximab) in clinical trials among people with relapsing forms of multiple sclerosis (MS) led to significantly fewer relapses...

Read source
multiplesclerosisnewstoday.com /3 weeks ago

EU regulators approve tolebrutinib, now Cenrifki, for nonrelapsing SPMS

Tolebrutinib has been approved in the European Union for the treatment of secondary progressive multiple sclerosis (SPMS) for people who have not experienced a relapse in the previ...

Read source
drugs.com /1 month ago

Chemo-Free Drug, Tecvayli, Shows Major Survival, Remission Gains In Relapsed Multiple Myeloma

WEDNESDAY, June 3, 2026 — A recently approved cancer immunotherapy can put nearly two-thirds of people with relapsed multiple myeloma into complete remission, a new clinical trial...

Read source
multiplesclerosisnewstoday.com /1 month ago

Latest preclinical data support promise of CAR-M cell therapy LIB820

Liberate Bio’s investigational CAR-M cell therapy LIB820 may help successfully eliminate disease-driving B-cells in autoimmune diseases such as multiple sclerosis (MS) without caus...

Read source
multiple-sclerosis-research.org /1 month ago

CLADLad time Middle Eastern Style

ProfK is a CladLad and has been flying the flag for many years. I put this paper up as it reinforces what I was saying about breaks after anti-CD20. Someone asked me if we will eve...

Read source
multiplesclerosisnewstoday.com /3 weeks ago

Researchers identify new therapeutic targets to combat MS progression

Scientists have identified six proteins that could serve as targets for new treatments designed to slow multiple sclerosis (MS) progression. The data showed that one protein, RRM2B...

Read source
drugs.com /1 month ago

Chemo-Free Drug Shows Major Survival, Remission Gains In Relapsed Multiple Myeloma

WEDNESDAY, June 3, 2026 — A recently approved cancer immunotherapy can put nearly two-thirds of people with relapsed multiple myeloma into complete remission, a new clinical trial...

Read source
multiple-sclerosis-research.org /3 weeks ago

Extending the intervals

Rituximab, ocrelizumab and ublituximab is given every 24 weeks This is done to maintain a low levels of B cell numbers. If you spend the time and expense to measure the reappearanc...

Read source
multiple-sclerosis-research.org /1 month ago

ChariotMSX

ChariotMS is coming of age. We started recruiting in July 2021, completed that in Jan 2025 and data lock for the 204 (of 200 planned) participants is in April 2027, so in less than...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.

Start creating posts

Sources covering Mavenclad

multiple-sclerosis-research.org

Recent coverage from public sources
Public source

multiplesclerosisnewstoday.com

Recent coverage from public sources
Public source

drugs.com

Recent coverage from public sources
Public source

Related searches

News Archive Experimental treatment clinical trials CMSC Annual Meeting treatment #ChariotMS Aubagio Drug approval Drug information MS relapse Mavenclad

Recent searches

Artificial Intelligence Machine Learning Data Science Data Engineering Business Intelligence Web Development Software Development Software Testing Programming JavaScript DevOps Cyber Security Product Management Project Management Design UX UX Research Graphic Design Video Production Video Editing